Long‐term oncological results of percutaneous radiofrequency ablation for intrahepatic cholangiocarcinoma
Liver International · 2024
DOI: 10.1111/liv.15886 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2024. Verfasst von Clémentine Alitti und 15 weiteren Autor:innen. Beteiligte Einrichtung: Liver Unit, Avicenne Hospital, APHP, Paris Nord University, Bobigny, France. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms, Radiofrequency Ablation, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Introduction
The effectiveness of percutaneous radiofrequency ablation (RFA) in intrahepatic cholangiocarcinomas (iCCA) remains insufficiently studied.
Methods
We conducted a retrospective study including patients with histologically proven iCCA within Milan criteria treated by percutaneous RFA from 2000 to 2022. The primary outcome was overall survival in treatment‐naive patients and secondary outcomes included ablation completeness, adverse events, local and distant recurrence. A total of 494 patients with hepatocellular carcinoma (HCC) on cirrhosis treated by RFA were included as a comparison group. Oncological events were analysed using Kaplan–Meier, log‐rank and univariate/multivariate Cox models.
Results
The main population included 71 patients, mostly cirrhotic (80%) with solitary tumours (66%) of a median size of 24 mm. Local recurrence was 45% at 5 years, lower in multibipolar versus monopolar RFA (22% vs. 55%, p = .007). In treatment‐naive patients ( n = 45), median overall and recurrence‐free survivals were 26 and 11 months, respectively. Tumour size ( p = .01) and Child‐Pugh B ( p = .001) were associated with death. The rate of distant recurrence was 59% at 5 years significantly lower for single tumours of less than 2 ( p = .002) or 3 cm ( p = .02). In cirrhotic patients naïve of previous treatment ( n = 40), overall survival was shorter than in HCC (26 vs 68 months, p < .0001), with more local recurrences ( p < .0001). Among distant recurrences, 50% were extrahepatic metastases compared to 12% in HCC ( p < .001).
Conclusion
Multibipolar RFA provides better results in terms of tumour recurrence than monopolar RFA and could be used to treat small iCCA (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Liver Unit, Avicenne Hospital, APHP, Paris Nord University, Bobigny, France.
- Department of Radiology, Hôpital Croix-Rousse, Hospices Civils de Lyon, Lyon, France.
- Department of Diagnostic and Interventional Radiology, University Hospital Bordeaux, Pessac, France.
- Cancer Research Center of Lyon (CRCL), INSERM U1052, Centre National de la Recherche Scientifique UMR5286, Lyon, France.
- Department of Hepatology, Hôpital Croix-Rousse, Hospices Civils de Lyon, Lyon, France.
- Department of Hepatogastroenterology, CHU Bordeaux, Bordeaux, France.
ORCID-Profile: Clémentine Alitti, Gisele Nkontchou, Marianne Ziol, Pierre Nahon, Jean-Charles Nault
Zitieren
APA
Alitti, C., Rode, A., Trillaud, H., Merle, P., Blanc, J. F., Blaise, L., Demory, A., Nkontchou, G., Grando, V., Ziol, M., Nahon, P., Ganne-Carrié, N., Petit, A., Seror, O., Sutter, O., & Nault, J. C. (2024). Long‐term oncological results of percutaneous radiofrequency ablation for intrahepatic cholangiocarcinoma. Liver International. https://doi.org/10.1111/liv.15886
Vancouver
Alitti C, Rode A, Trillaud H, Merle P, Blanc JF, Blaise L, et al. Long‐term oncological results of percutaneous radiofrequency ablation for intrahepatic cholangiocarcinoma. Liver International. 2024. doi:10.1111/liv.15886
BibTeX
@article{Alitti2024,
author = {Alitti, Clémentine and Rode, Agnès and Trillaud, Hervé and Merle, Philippe and Blanc, Jean-Frédéric and Blaise, Lorraine and Demory, Alix and Nkontchou, Gisele and Grando, Véronique and Ziol, Marianne and Nahon, Pierre and Ganne-Carrié, Nathalie and Petit, Arthur and Seror, Olivier and Sutter, Olivier and Nault, Jean-Charles},
title = {Long‐term oncological results of percutaneous radiofrequency ablation for intrahepatic cholangiocarcinoma},
journal = {Liver International},
year = {2024},
doi = {10.1111/liv.15886}
}
EUVIMED